Connecticut med spa & injectable regulations
What’s changing for med spas and injectors in Connecticut — GLP-1 compounding, scope-of-practice, and enforcement — plus the federal FDA and Federal Register actions that apply in Connecticut. Med Spa Radar monitors it all and tells you, in plain language, what changed and what to do.
Opening a med spa? We have not verified Connecticut’s rules against the statute yet, so start with what opening a med spa requires →
Latest Connecticut changes
No Connecticut-specific changes have crossed our radar yet — we’re actively monitoring the Connecticut legislature and licensing boards. The federal changes below apply to every Connecticut practice today.
Federal changes that apply in Connecticut
FDA and Federal Register actions are nationwide — they govern Connecticut practices too.
- CAUTIONFEDERALFederal RegisterJul 30, 2026
FDA / Federal Register Notice: Outsourcing Facility Fee Rates for Fiscal Year 2027
New FDA fees for outsourcing facilities will impact med spas using compounds.
- CRITICALFEDERALFDA Warning LetterJul 8, 2026
FDA Warning Letter: Spa De Soleil, Inc. (Drugs)
FDA warns Spa De Soleil over drug compounding practices.
- MONITORFEDERALFederal RegisterJun 26, 2026
FDA / Federal Register Notice: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
FDA extends comment period on GLP-1 compounding decisions.
- CRITICALFEDERALFDA Warning LetterJun 23, 2026
FDA Warning Letter: ketaminelab.org (Drugs)
FDA Warning Letter issued to ketaminelab.org for drugs.
- CRITICALFEDERALFTC EnforcementJun 12, 2026
FTC Files Contempt Motion Against Amare Global and Three Individuals Over Unsubstantiated Health Claims
FTC targets deceptive health claims affecting aesthetic practices.
- CAUTIONFEDERALFDA Drug ShortagesJun 11, 2026
FDA shortage: Liraglutide Injection (Injection) — Currently in Shortage
Liraglutide is still on the FDA shortage list for compounding.
What we monitor in Connecticut
- Connecticut legislature — bills on injectables, GLP-1s & scope of practice
- Connecticut Board of Nursing — injector scope & delegation
- Connecticut Medical Board — physician supervision & ownership rules
- Connecticut Board of Pharmacy — compounding & 503A/503B
- U.S. FDA — enforcement, warning letters, recalls, shortages
- Federal Register — new rules on compounding & aesthetics
Connecticut med spa compliance — FAQ
- Where do Connecticut med spa and injectable regulations come from?
- Connecticut med spas and injectors are governed by a mix of state and federal authorities — the Connecticut legislature, and the state's boards of nursing, medicine, and pharmacy, alongside federal bodies like the FDA and the Federal Register. Med Spa Radar monitors all of them for Connecticut and flags what changed in plain language.
- Does the FDA's GLP-1 compounding guidance apply in Connecticut?
- Yes — federal FDA actions on GLP-1 compounding (semaglutide, tirzepatide) apply nationwide, including in Connecticut. We track those federal changes alongside any Connecticut-specific rules so you see the full picture for your practice.
- How do I keep up with Connecticut regulatory changes?
- Med Spa Radar sends a free weekly Brief on what changed across Connecticut, the FDA, and the Federal Register. Members get the exact "what to do" for their states in real time. It's regulatory monitoring, not legal advice.
Get Connecticut changes as they publish
We scan the Connecticut legislature and licensing boards daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.
Free · unsubscribe in one click · we never sell your address
← All states · Regulatory monitoring, not legal advice.